EMC-AANL-DOX
EMC-AANL-DOX is a legumain-activated prodrug conjugate of Doxorubicin (DOX). EMC-AANL-DOX shows antitumor activity in mouse models of neuroblastoma (NB), breast cancer (4T1), fibrosarcoma (HT1080), and colorectal cancer liver metastases (CT26). EMC-AANL-DOX can be used for cancer research[1][2].
Product Specifications
CAS Number
1431625-66-9
UNSPSC
12352203
Target
Others
Related Pathways
Others
Field of Research
Cancer
Smiles
OC1=C(C(C2=CC=CC(OC)=C2C3=O)=O)C3=C(O)C4=C1C[C@](C(CO)=O)(O)C[C@@H]4O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)NC([C@H](CC(C)C)NC([C@H](CC(N)=O)NC([C@H](C)NC([C@H](C)NC(CCCCCN6C(C=CC6=O)=O)=O)=O)=O)=O)=O
Molecular Formula
C53H67N7O19
Molecular Weight
1106.13
References & Citations
[1]Zhang M, et al. Legumain correlates with neuroblastoma differentiation and can be used in prodrug design. Chem Biol Drug Des. 2018 Feb;91 (2) :534-544.|[2]Cheng Liu, et al. Immune-stimulating soluble doxorubicin-conjugated complex. US20200247842. 2022-05-03.
Shipping Conditions
Room temperature
Scientific Category
ADC Related
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC681295-500 1x 500 µL
HPV-16 (Human Papilloma Virus 16) (HPV16/1295), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
